Xenetic Biosciences, Inc.
NASDAQ: XBIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James F. Parslow
- Employees
- 2
- Headquarters
- Framingham, United States
- IPO year
- 2016
- Market cap
- $5.5M
- Website
- https://www.xeneticbio.com
Loading XBIO…
Loading profile data…Frequently asked questions about XBIO
What does Xenetic Biosciences, Inc. (XBIO) do?
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company...
Where does XBIO trade?
Xenetic Biosciences, Inc. (XBIO) trades on the NASDAQ Capital Market.
What sector is XBIO in?
Xenetic Biosciences, Inc. (XBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Xenetic Biosciences, Inc.?
James F. Parslow is the chief executive officer of Xenetic Biosciences, Inc. (XBIO).
Where is Xenetic Biosciences, Inc. headquartered?
Xenetic Biosciences, Inc. is headquartered in United States.
Does XBIO pay a dividend?
Xenetic Biosciences, Inc. (XBIO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XBIO go public?
Xenetic Biosciences, Inc. (XBIO) completed its initial public offering in 2016.